

JesÃ³s Duque-Afonso

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6361336/publications.pdf>

Version: 2024-02-01

31
papers

383
citations

759055

12
h-index

839398

18
g-index

33
all docs

33
docs citations

33
times ranked

703
citing authors

#	ARTICLE	IF	CITATIONS
1	Structured assessment of frailty in multiple myeloma as a paradigm of individualized treatment algorithms in cancer patients at advanced age. <i>Haematologica</i> , 2020, 105, 1183-1188.	1.7	46
2	The HDAC class I-specific inhibitor entinostat (MS-275) effectively relieves epigenetic silencing of the LAT2 gene mediated by AML1/ETO. <i>Oncogene</i> , 2011, 30, 3062-3072.	2.6	45
3	Transitioning the Molecular Tumor Board from Proof of Concept to Clinical Routine: A German Single-Center Analysis. <i>Cancers</i> , 2021, 13, 1151.	1.7	27
4	Droplet digital PCR for the simultaneous analysis of minimal residual disease and hematopoietic chimerism after allogeneic cell transplantation. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 57, 641-647.	1.4	25
5	Identification of risk factors for bronchiolitis obliterans syndrome after reduced toxicity conditioning before hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2013, 48, 1098-1103.	1.3	20
6	SETDB2 Links E2A-PBX1 to Cell-Cycle Dysregulation in Acute Leukemia through CDKN2C Repression. <i>Cell Reports</i> , 2018, 23, 1166-1177.	2.9	20
7	Cell-free DNA characteristics and chimerism analysis in patients after allogeneic cell transplantation. <i>Clinical Biochemistry</i> , 2018, 52, 137-141.	0.8	19
8	Impact of Lung Function on Bronchiolitis Obliterans Syndrome and Outcome after Allogeneic Hematopoietic Cell Transplantation with Reduced-Intensity Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2277-2284.	2.0	19
9	AML1/ETO and its function as a regulator of gene AML transcription via epigenetic mechanisms. <i>Oncogene</i> , 2021, 40, 5665-5676.	2.6	18
10	Inhibition of precursor B-cell malignancy progression by toll-like receptor ligand-induced immune responses. <i>Leukemia</i> , 2016, 30, 2116-2119.	3.3	15
11	Phenotypical and functional analysis of donor lymphocyte infusion products after long-term cryopreservation. <i>Transfusion and Apheresis Science</i> , 2020, 59, 102594.	0.5	14
12	Regulation of the adaptor molecule LAT2, an <i>in vivo</i> target gene of AML1/ETO (<i>RUNX1/RUNX1T1</i>), during myeloid differentiation. <i>British Journal of Haematology</i> , 2011, 153, 612-622.	1.2	13
13	The epigenetics of breast cancer – Opportunities for diagnostics, risk stratification and therapy. <i>Epigenetics</i> , 2022, 17, 612-624.	1.3	13
14	Prognostic factors for survival after allogeneic transplantation in acute lymphoblastic leukemia. <i>Bone Marrow Transplantation</i> , 2021, 56, 841-852.	1.3	12
15	The AML1/ETO target gene LAT2 interferes with differentiation of normal hematopoietic precursor cells. <i>Leukemia Research</i> , 2014, 38, 340-345.	0.4	10
16	Ibrutinib in patients with relapsed/refractory central nervous system lymphoma: A retrospective single-centre analysis. <i>British Journal of Haematology</i> , 2020, 190, e110-e114.	1.2	10
17	The impact of pulmonary function in patients undergoing autologous stem cell transplantation. <i>Blood Advances</i> , 2021, 5, 4327-4337.	2.5	9
18	Personalized Treatment Selection and Disease Monitoring Using Circulating Tumor DNA Profiling in Real-World Cancer Patient Management. <i>Diagnostics</i> , 2020, 10, 550.	1.3	8

#	ARTICLE	IF	CITATIONS
19	Comparison of reduced-toxicity conditioning protocols using fludarabine, melphalan combined with thiotepa or carmustine in allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 2021, 56, 110-120.	1.3	8
20	Loss of the Fanconi anemia-associated protein NIPA causes bone marrow failure. Journal of Clinical Investigation, 2020, 130, 2827-2844.	3.9	8
21	Functional characterization of the PI3K/AKT/MTOR signaling pathway for targeted therapy in B-precursor acute lymphoblastic leukemia. Cancer Gene Therapy, 2022, 29, 1751-1760.	2.2	7
22	Comparison of fludarabine-melphalan and fludarabine-treosulfan as conditioning prior to allogeneic hematopoietic cell transplantation a registry study on behalf of the EBMT Acute Leukemia Working Party. Bone Marrow Transplantation, 2022, 57, 1269-1276.	1.3	6
23	Differential Depletion of Bone Marrow Resident B-ALL after Systemic Administration of Endosomal TLR Agonists. Cancers, 2020, 12, 169.	1.7	5
24	Colon and liver tissue damage detection using methylated SESN3 and PTK2B genes in circulating cell-free DNA in patients with acute graft-versus-host disease. Bone Marrow Transplantation, 2021, 56, 327-333.	1.3	5
25	Monitoring of Measurable Residual Disease Using Circulating DNA after Allogeneic Hematopoietic Cell Transplantation. Cancers, 2022, 14, 3307.	1.7	1
26	Epigenetic Repression of the Adaptor Molecule LAT2 by the Leukemic Fusion Protein AML1/ETO.. Blood, 2007, 110, 987-987.	0.6	0
27	The AML1/ETO Target LAT2 Membrane Adaptor Molecule Is Regulated during Normal Monocytic Differentiation.. Blood, 2007, 110, 2401-2401.	0.6	0
28	Low Incidence of Pulmonary Graft-Versus-Host Disease in Older Patients After Reduced Toxicity Conditioning with FBM Prior to Hematopoietic Stem Cell Transplantation.. Blood, 2009, 114, 4660-4660.	0.6	0
29	Re-Expression of the AML1/ETO Target Gene LAT2/NTAL/LAB Results In Direct Interference with Myeloid Differentiation In AML1/ETO-Positive Cells. Blood, 2010, 116, 2474-2474.	0.6	0
30	Pulmonary Graft-Versus-Host Disease After Reduced Toxicity Conditioning with Fludarabin, Carmustine and Melphalan Prior to Hematopoietic Stem Cell Transplantation. Blood, 2010, 116, 1266-1266.	0.6	0
31	The Fanconi Anemia-Associated Protein NIPA Is Essential for the Nuclear Abundance of FANCD2. Blood, 2019, 134, 3741-3741.	0.6	0